Policy & Regulation
Lantern Pharma advances EMA-cleared Phase 1b/2 bladder cancer trial for LP-184
28 July 2026 - Clinical-stage, AI-native biopharma company Lantern Pharma Inc (NASDAQ:LTRN) said on Tuesday that the European Medicines Agency (EMA) has cleared an investigator-initiated Phase 1b/2 cl...
DifGen Pharmaceuticals' single injection treatment for advanced breast cancer cleared for clinical development
28 July 2026 - Generic pharmaceuticals manufacturer DifGen Pharmaceuticals LLC announced on Monday that the US Food and Drug Administration (FDA) has accepted the company's Investigational New Dr...
AbelZeta's C-CAR168 registrational Phase II trial in refractory Lupus Nephritis granted FDA clearance
28 July 2026 - Clinical-stage biopharmaceutical company AbelZeta Pharma Inc announced on Monday the receipt of US Food and Drug Administration (FDA) clearance under its Regenerative Medicine Advanced ...
CSL reports positive top-line Phase 3b results for ANDEMBRY (garadacimab-gxii) in children with HAE
28 July 2026 - Australia-based global biotechnology company CSL (ASX:CSL; USOTC:CSLLY) announced on Monday positive top-line Phase 3b results evaluating ANDEMBRY (garadacimab-gxii) in children aged 2 ...
Yarrow Bioscience completes VYNE merger and begins Phase 2 trial of YB-101
27 July 2026 - Clinical-stage biotechnology company Yarrow Bioscience Inc (Nasdaq:YARW) announced on Monday that it has completed its merger with VYNE Therapeutics Inc and closed previously announced ...
Harbour BioMed and Sinopharm establish innovation R&D consortium
27 July 2026 - Biopharmaceutical company Harbour BioMed (HKEX: 02142) declared on Monday that it has entered into a strategic collaboration with China National Pharmaceutical Group Co Ltd (Sinopharm) ...